Official ESCRS | European Society of Cataract & Refractive Surgeons

Innovative process for the elaboration of sustained drug delivery intraocular lenses

Session Details

Session Title: Cataract 2
Session Date/Time: Saturday 21/02/2015 | 08:30-11:00
Paper Time: 08:42
Venue: Hall 1
First Author: : J.Andre FRANCE
Co Author(s): :    A. Bouledjouidja   Y. Masmoudi   O. Forzano   E. Badens     

Abstract Details


The present work deals with the development of drug delivery intraocular lenses (IOLs) to prevent postoperative endophthalmitis in cataract surgery. Commercially available foldable IOLs were impregnated with an anti-inflammatory drug and with an antibiotic using an innovative and green process. The impregnated IOLs act as Drug Delivery Systems (DDS). Drug impregnation is significant while the transparency and optical properties are preserved. Drug is then released over days following surgery. The innovative aspect of the process is that no toxic organic solvents are used; the impregnated IOLs are then clean.


In order to prevent postoperative infectious complications, a solution can be the use of controlled Drug Delivery Systems placed inside the eye. If the DDS is the impregnated IOL, this solution does not require an additional act of the surgeon.


Supercritical fluid technologies have been demonstrated to be a clean and effective alternative to traditional methods of drug and polymer processing. Commercially available rigid IOLs made from derivative of Poly 2-hydroxyethyl methacrylate have been impregnated with Dexamethasone 21-phosphate disodium and with Ciprofloxacine through a discontinuous process under different conditions of pressure (8 and 20 MPa) and temperature (308 and 333 K). Supercritical carbon dioxide has been used as the impregnation solvent. Drug loading and drug release kinetics have been characterized for each impregnated IOL. The transparency and optical properties of processed IOLs have also been evaluated.


Depending on the operating conditions, the drug impregnation yields vary from 0.1 to 8.0 wt % (± 0.1 %). For some samples and for certain conditions, a foaming phenomenon has been observed. Indeed, in presence of dense carbon dioxide, the polymeric implants plasticize. Thus, during the depressurization step, bubbles of CO2 can be formed within the polymeric matrix. An innovative pre-treatment step has been implemented in order to avoid this foaming phenomenon. In vitro drug release studies have been performed in a solution simulating the aqueous humor. Drug release is observed during a period varying from ten to forty days.


An innovative process for the drug impregnation of IOLs has been implemented. IOLs can act as Drug Delivery Systems once placed in the eyes at the end of surgery. The impregnation rates obtained are significant and the in vitro drug release studies have shown that the drug is released over a period comprised between ten and forty days. This process applied to IOLs can also be adapted to any polymeric matrix or implant for which a drug impregnation is required. The impregnation can also be carried out using a mixture of drugs.

Financial Disclosure:


Back to previous